Johnny Hu
Overview
As a principal at Menlo Ventures, Johnny invests in biotech and life science companies with a focus on novel therapeutics and new technologies for improving medical outcomes. He has firsthand experience working at the bench on engineering new tools for the clinic. While completing his Ph.D., Johnny helped develop gene editing technologies that were licensed by companies such as Editas Medicine (NASDAQ: EDIT) and Beam Therapeutics (NASDAQ: BEAM). He is excited about partnering with founders at the beginning of the company journey to translate groundbreaking science into new medicines. Prior to Menlo, Johnny was a vice president at Longitude Capital, where he made several investments in early-stage biotech companies. He was a board observer at Lexeo Therapeutics, Endeavor Biomedicines, and Opna IO, and was on the investment team for Amunix Pharmaceuticals. Before Longitude, he was an associate at Omega Funds, where he worked on the firm’s investment in Nuvation Bio (NYSE: NUVB).
Reach Johnny Hu directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Johnny Hu
What sectors does Johnny Hu invest in?
Johnny Hu invests in BioTech, Consumer, Cybersecurity, FinTech, Healthcare and Logistics, and is based in San Francisco, California. Johnny Hu is listed as a investor in the ConnectSafely investor database.
What stage does Johnny Hu invest at?
Johnny Hu backs companies at Seed, Series A and Series B, writing cheques of $100K - $500K.
Which regions does Johnny Hu invest in?
Johnny Hu invests across US/Canada.
How do I contact Johnny Hu?
Johnny Hu's contact details — including work email and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of the team.
Last updated · Source: ConnectSafely investor database